Top Markets
Coin of the day
Cortexyme, Inc. Cortexyme, Inc.

Cortexyme, Inc.

CRTX
Rank in Stocks #25183
Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to... Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to pioneering new therapies for Alzheimer's and various other degenerative conditions. The company's primary investigational drug, atuzaginstat (also known as COR388), is an orally delivered, small molecule inhibitor engineered to cross the blood-brain barrier and target gingipain. This compound is currently in Phase II/III clinical trials, where it is being assessed for its potential use in individuals with mild to moderate Alzheimer's disease, as well as for tackling oral squamous cell carcinoma, periodontitis, and coronavirus infections. Established in 2012, Cortexyme, Inc. is headquartered in South San Francisco, California.
Share Price
$1.95
Last synced: 2022-07-29
Market Cap
$52.48M
Change (1 day)
2.63%
Change (1 year)
0.00%
Country
US
Trade Cortexyme, Inc. (CRTX)

Category

Operating Margin for Cortexyme, Inc. (CRTX)
Operating Margin as of 2026 TTM: 0.00%
According to Cortexyme, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Cortexyme, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.59% -
US
28.81% -
NL
25.72% -
AU
0.00% -
CH
-149.01% -
US
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.